NO331682B1 - Medisinsk anvendelse av histon-deacetylase inhibitor. - Google Patents

Medisinsk anvendelse av histon-deacetylase inhibitor. Download PDF

Info

Publication number
NO331682B1
NO331682B1 NO20040731A NO20040731A NO331682B1 NO 331682 B1 NO331682 B1 NO 331682B1 NO 20040731 A NO20040731 A NO 20040731A NO 20040731 A NO20040731 A NO 20040731A NO 331682 B1 NO331682 B1 NO 331682B1
Authority
NO
Norway
Prior art keywords
tumor
expression
gene
histone deacetylase
cell
Prior art date
Application number
NO20040731A
Other languages
English (en)
Norwegian (no)
Other versions
NO20040731L (no
Inventor
Yuka Sasakawa
Yoshinori Naoe
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of NO20040731L publication Critical patent/NO20040731L/no
Publication of NO331682B1 publication Critical patent/NO331682B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20040731A 2001-08-21 2004-02-20 Medisinsk anvendelse av histon-deacetylase inhibitor. NO331682B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001250846 2001-08-21
PCT/JP2002/008355 WO2003015810A1 (en) 2001-08-21 2002-08-20 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof

Publications (2)

Publication Number Publication Date
NO20040731L NO20040731L (no) 2004-04-20
NO331682B1 true NO331682B1 (no) 2012-02-20

Family

ID=19079582

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040731A NO331682B1 (no) 2001-08-21 2004-02-20 Medisinsk anvendelse av histon-deacetylase inhibitor.

Country Status (14)

Country Link
US (1) US8470783B2 (es)
EP (1) EP1426054B1 (es)
JP (1) JP4238728B2 (es)
AT (1) ATE526029T1 (es)
CA (1) CA2457043A1 (es)
DK (1) DK1426054T3 (es)
ES (1) ES2371630T3 (es)
HU (1) HU229521B1 (es)
MX (1) MXPA04001612A (es)
NO (1) NO331682B1 (es)
PL (1) PL210794B1 (es)
PT (1) PT1426054E (es)
RU (1) RU2298414C2 (es)
WO (1) WO2003015810A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673888B2 (en) * 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1595952A4 (en) * 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
DK2238982T3 (da) 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
CA2540108A1 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
WO2005058298A2 (en) * 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
WO2005059167A1 (en) * 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for identifying histone deacetylase inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
KR101167601B1 (ko) * 2004-02-25 2012-07-27 아스텔라스세이야쿠 가부시키가이샤 항종양제
JP2006000113A (ja) * 2004-05-20 2006-01-05 Masatomo Sakurai 漢方医療の診断に用いる遺伝子およびその利用方法
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
WO2006094068A2 (en) 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN102579417B (zh) 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
EP2361619A1 (en) 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
EP1965824A4 (en) * 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
CA2649877A1 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
JP2010514801A (ja) 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンの精製
CA2674313A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
EA201201640A1 (ru) 2007-01-30 2013-09-30 Фармасайкликс, Инк. Способы определения устойчивости рака к ингибиторам гистондеацетилазы
CA2700173C (en) 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
MX342913B (es) 2010-07-12 2016-10-19 Celgene Corp * Formas solidas de romidepsina y sus usos.
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
KR20010023449A (ko) * 1997-09-02 2001-03-26 나가시마 카쭈시게, 노미야마 아키히코 신규한 환상 테트라펩티드 유도체 및 그 의약 용도
WO1999022773A2 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
MXPA02002505A (es) 1999-09-08 2004-09-10 Sloan Kettering Inst Cancer Nueva clase de agentes de citodiferenciacion e inhibidores de histona desacetilasa y metodos de utilizacion de los mismos.
CA2393682C (en) 1999-12-08 2012-01-31 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) * 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
ATE425177T1 (de) * 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
US8673888B2 (en) * 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
DK2238982T3 (da) * 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
CA2540108A1 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
CA2457043A1 (en) 2003-02-27
US20050191713A1 (en) 2005-09-01
ES2371630T3 (es) 2012-01-05
HU229521B1 (hu) 2014-01-28
DK1426054T3 (da) 2011-12-12
PT1426054E (pt) 2011-12-06
EP1426054A1 (en) 2004-06-09
HUP0400668A3 (en) 2012-09-28
US8470783B2 (en) 2013-06-25
PL210794B1 (pl) 2012-03-30
ATE526029T1 (de) 2011-10-15
PL368708A1 (en) 2005-04-04
RU2004108137A (ru) 2005-05-10
NO20040731L (no) 2004-04-20
MXPA04001612A (es) 2004-07-08
JP4238728B2 (ja) 2009-03-18
HUP0400668A2 (hu) 2005-01-28
JPWO2003015810A1 (ja) 2004-12-02
EP1426054A4 (en) 2006-09-13
EP1426054B1 (en) 2011-09-28
WO2003015810A1 (en) 2003-02-27
RU2298414C2 (ru) 2007-05-10

Similar Documents

Publication Publication Date Title
US8470783B2 (en) Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
WO2004074478A1 (ja) ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
JP2019131546A (ja) がん患者におけるがんの治療方法及び薬物応答性の予測方法
US12569538B2 (en) DPEP-1 binding compositions and methods of use
JP6900320B2 (ja) がんにおけるマイクロピノサイトーシス
US20060135413A1 (en) Depsipeptide for therapy of kidney cancer
MX2011004344A (es) Terapia contra el cancer.
Nakamura et al. Osteopontin-integrin αvβ3 axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma
KR20210022669A (ko) 펩타이드를 사용하는 병용 요법
EP4335920A2 (en) Use of rhoa in cancer diagnosis and inhibitor screening
JP7291327B2 (ja) ペプチド誘導体及びそれを含む医薬組成物
Johnson New targets for lymphoma treatment
JP6659250B2 (ja) 癌の検査方法、癌細胞増殖阻害剤、抗癌剤及び抗癌剤のスクリーニング方法
Gu et al. A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies
KR101308940B1 (ko) 프로테아좀 저해제 및 쥐알파12/쥐알파13 단백질 기능의 하향 조절제를 포함하는 의약 조성물
CN118852344A (zh) 一种用于预防和/或治疗食道癌的肽及其用途
Scheiterle et al. 353. PIK3CA mutation in gastric cancer and the role of different codon mutations in the new molecular division of that neoplasm
CN113122627A (zh) Igfl4基因作为标志物在胃癌、结直肠癌、子宫内膜癌及卵巢癌中诊断及治疗的应用
EP2578227A2 (en) Cancer therapy method
Chinni The Role of ERG and CXCR4 in Prostate Cancer Progression

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

MM1K Lapsed by not paying the annual fees